TB-500 is a synthetic heptapeptide, Leu-Lys-Lys-Thr-Glu-Thr-Gln, carrying an acetyl group on its N-terminal leucine — written Ac-LKKTETQ. Those seven residues are not arbitrary: they reproduce residues 17–23 of mature human thymosin β4, a 43-residue protein, and they contain the LKKTET motif of its central actin-binding domain [1, 2]. The N-terminal acetylation is a synthetic addition, not a feature the fragment has inside the parent protein, and the TB-500 formulation examined in a doping-control laboratory was shown by high-resolution mass spectrometry to contain exactly this acetylated 17–23 fragment [1].

That distinction matters more than it first appears. TB-500 is routinely described as "the active site of thymosin β4," which invites the assumption that it is a smaller version of the protein with the same behavior. The structural and analytical literature does not support that assumption, and the most direct test of it — an assay comparing the acetylated heptapeptide against its own breakdown products — found no significant wound-closure activity for the acetylated parent itself [3]. This guide sets out what has actually been measured, in what systems, and where the record is empty.

Identity and characterization

The identity data below are the values Echo Peptides publishes for this compound and are the ones a receiving lab should reconcile against an incoming certificate of analysis.

Two identity confusions are worth naming because both appear in circulation. The first is between TB-500 and full-length thymosin β4, which is a separate substance of roughly 4,963 Da and a separate PubChem record; a certificate reporting a mass near 4,900 Da is not describing this compound. The second is between the acetylated and unacetylated seven-residue peptides. Free LKKTETQ and Ac-LKKTETQ differ by 42 Da, they are distinguishable by mass spectrometry, and — as the sections below show — most of the published biology belongs to the unacetylated form. A certificate that reports only purity by HPLC area percent does not settle which of the two is in the vial; confirmatory mass data does.

Ac-LKKTETQ has been prepared by solid-phase peptide synthesis and used as a synthesized authentic standard, so a reference material for identity comparison exists in the literature [1, 3].

Mechanism as studied

Thymosin β4 is described in the review literature as the major actin-sequestering molecule in eukaryotic cells [2], and β-thymosins are described as maintaining monomeric actin in a sequestered, nonpolymerizable form [6]. The LKKTET motif is genuinely part of that interface. Peptide-mimetic and substitution work localized the actin-binding site of thymosin β4 to roughly twenty residues and dissected it into two functional entities — a conserved hexapeptide motif (LKKTET) that forms the major contact through electrostatic interactions with actin, and a non-conserved N-terminal segment preceding the motif that supplies the inhibition of polymerization, probably through steric hindrance [4]. Introducing a single glutamic acid into the motif, giving LKETET, converted the peptide's inhibitory phenotype into an F-actin-stimulatory one [4].

Mutational analysis of full-length thymosin β4 variants reached a compatible conclusion by a different route: residues 1–16 and the 17–22 hexapeptide form separate structural entities, the N-terminal region has to adopt an α-helix to bind actin and contacts it through a hydrophobic patch on one face, and lysine residues inside and outside the motif contribute electrostatically [5]. Structural work on the wider β-thymosin/WH2 family described the same asymmetry: the region showing the strongest interaction with actin is the amphipathic N-terminal α-helix present in all these domains, while weaker C-terminal contacts govern whether the domain inhibits or promotes assembly [6].

Read together, these three lines of evidence say something specific about TB-500. The heptapeptide carries the contact motif but neither the N-terminal α-helix reported as the strongest actin-interacting region, nor the flanking segment to which the inhibition of polymerization was assigned [4, 5, 6]. No measured dissociation constant for Ac-LKKTETQ with G-actin appears in this literature. Describing the compound as "the actin-binding domain" is accurate as sequence provenance and unproven as a statement of function.

It is worth being explicit about what the underlying assays measure, because the phrase "actin-binding" is doing a lot of work. The binding site was localized with peptide mimetics [4]; the mapping of chemically synthesized full-length variants rests on chemical cross-linking, complex formation in native gels, actin-sequestering experiments and circular dichroism [5]; and the family-level model rests on crystallographic, NMR and mutagenetic data [6]. These are measurements on purified components rather than on cells. They establish an interaction and its geometry; they do not by themselves establish what a peptide does when added to a cell culture, and none of them has been reported for the acetylated heptapeptide.

Beyond actin, one candidate mechanism has been floated for the free heptapeptide and not resolved. Investigators who recovered thymosin β4 and β10 peptides from skin wound fluid using capillary ultrafiltration probes reported that LKKTETQ enhanced closure in their assays and suggested the effect may be mediated by purinergic receptors [7]. That is a hypothesis stated as one, in a proteomics paper; no receptor has been identified, no binding assay reported, and nothing in that work concerned the acetylated form.

Model systems it has been examined in

The unacetylated peptide

The seven-residue peptide LKKTETQ, without acetylation, promoted repair in full-thickness dermal wound models in aged mice to a degree comparable with the full-length parent protein [8]. A review of thymosin β4's active sites assigns angiogenesis, wound healing and cell migration activity to this central 17–23 sequence, and separate activities — anti-inflammatory and anti-apoptotic effects — to distinct N-terminal sites [2]. On that mapping, the fragment would not be expected to reproduce the protein's full activity profile.

In cultured human hepatic stellate cells stimulated with PDGF-BB, the 17–23 peptide, but not a 15-residue N-terminal peptide, blunted the up-regulation of the PDGFβ receptor, α-smooth-muscle actin and collagen 1. The 17–23 peptide also reduced Akt phosphorylation at both T308 and S473 with corresponding loss of PRAS40 phosphorylation, and inhibited proliferation and migration in that system; the 15-residue peptide is reported there as blocking Akt phosphorylation at S473 but not T308, with no effect on proliferation or migration [9]. This is one of the cleaner mechanism-linked datasets for the sequence, because it compares two defined fragments in the same assay and reports a signaling readout rather than an endpoint alone. The 17–23 peptide is reported there without N-terminal acetylation.

The acetylated peptide — TB-500 as sold

The compound itself has been studied most thoroughly by analytical chemists rather than cell biologists. A 2024 study synthesized authentic standards of Ac-LKKTETQ and its truncation products, quantified them by UHPLC-Orbitrap MS in human serum, in defined enzyme systems and in rat urine, and then screened the same species in fibroblast wound-closure assays [3]. Three findings are relevant to anyone working with this material. Ac-LK was the metabolite present at the highest concentration in rats over the first six hours, and Ac-LKK persisted longest, detected out to 72 hours. Neither the parent nor its metabolites showed cytotoxicity. And of everything tested, only the intermediate fragment Ac-LKKTE showed significant wound-closure activity relative to control — the intact acetylated parent did not. The authors' own reading is hedged and worth preserving: previously reported wound-healing activity of TB-500 may be attributable to a metabolite rather than to the parent form [3].

Doping-control laboratories have independently characterized the molecule's fate. An LC-MS method identified Ac-LKKTETQ and its metabolites in equine plasma and urine following administration, with confirmation limits of 0.02 ng/mL in plasma and 0.01 ng/mL in urine [10]. The practical implication for in vitro work is the same in either species: in any matrix containing serum peptidases, the intact heptapeptide is one component of a changing mixture, not a fixed reagent.

What the evidence does not establish

This is the section that most descriptions of TB-500 omit, and the gaps are substantive.

  • Activity data and product identity do not line up. The dermal repair, migration and angiogenesis findings usually cited for TB-500 were generated with unacetylated LKKTETQ or with full-length thymosin β4 [2, 7, 8]. The single published study that tested the acetylated compound directly in a functional assay found no significant activity for it there [3].
  • No binding constant exists for the acetylated heptapeptide. Binding-site mapping and structural data are available for the parent protein and for β-thymosin/WH2 domains [4, 5, 6], not for Ac-LKKTETQ.
  • No receptor has been identified. The purinergic suggestion is an unfollowed lead [7], and the actin interaction is a protein–protein contact, not receptor pharmacology.
  • Concentration-matched comparisons are missing. There is no published head-to-head of Ac-LKKTETQ against unacetylated LKKTETQ and against full-length thymosin β4 at matched molarity in a single assay system, which is the experiment that would settle the fragment-versus-protein question.
  • Effects in composite delivery systems are not attributable to the free peptide. A 2025 report incorporated the sequence, given there as LKKTETQ, into an alkaline-phosphatase-triggered self-assembling peptide hydrogel formed from the phosphorylated precursor Nap-YpYY-TB500; what that work evaluated is the assembled construct, not the free acetylated heptapeptide [11].
  • The preclinical record has not been extended. A 2026 narrative review of peptide therapies in orthopedic and sports medicine concluded that thymosin β4 and TB-500 promoted angiogenesis and tissue repair in preclinical models, and that human orthopedic data are lacking [12].

None of this makes the compound uninteresting. It makes it an open question with a well-defined sequence, which is a reasonable thing to buy for laboratory work and a poor thing to describe as established.

Handling and stability

Two published observations bear directly on bench technique.

First, surface adsorption has been evaluated for this specific peptide, and consumable choice measurably changes recovery. TB-500 was one of four peptides used in a systematic study of recovery from different labware, undertaken precisely because analytes at ng/mL to pg/mL concentrations can be lost to container walls; the study also found that expensive low-bind consumables were not uniformly better, and recommended selecting consumables against the physicochemical properties of the individual peptide [13]. At working concentrations in that range, a recovery check in your own tubes and plates is a measurement, not a precaution.

Second, the peptide is truncated by serum and by defined enzyme systems, generating Ac-LKKTE, Ac-LKK and Ac-LK among other species [3]. Any incubation in serum-containing medium therefore exposes cells to a mixture, and — given that Ac-LKKTE was the only species showing a significant wound-closure effect relative to control in that work — the composition of the mixture is not a nuisance variable but a plausible determinant of the result.

On the lyophilized material itself, the honest statement is that the peer-reviewed literature contains no systematic stability study of lyophilized Ac-LKKTETQ: no published shelf-life curve, no freeze–thaw series, no comparison of reconstitution diluents. The compound is supplied as a lyophilized powder for storage at 2–8 °C, and identity and purity claims rest on the accompanying certificate of analysis and its scope, not on published stability data.

That absence has a practical consequence. Common bench conventions for reconstituted peptides — single-use aliquots, avoidance of repeated freeze–thaw, protection from light — are reasonable defaults, but for Ac-LKKTETQ specifically they are conventions rather than findings, and a laboratory that needs a defined shelf life will have to generate its own purity-over-time data rather than cite anyone else's. The same applies to the certificate: read which vial size and which batch it was issued against, and whether it reports a purity figure at all, before treating it as characterization of the material in hand.

Open questions

The productive experiments here are unglamorous and specific. Does Ac-LKKTETQ bind G-actin at all, and with what affinity relative to the unacetylated heptapeptide and to the intact protein? If the 2024 result generalizes, and the acetylated parent is a precursor to Ac-LKKTE, does that hold across cell types and assay formats, or only in fibroblast closure assays [3]? What accounts for the difference between the fragment's clear effect on PDGF-BB-driven Akt signaling in hepatic stellate cells [9] and the absence of a significant effect for the acetylated parent in the fibroblast closure assay [3] — acetylation, cell type, concentration, or exposure time? And is the purinergic receptor lead [7] reproducible with defined agonists and antagonists?

Until those are answered, the defensible summary is short. TB-500 is a well-characterized, commercially available heptapeptide whose sequence is drawn from a real actin-binding motif; the biology usually attributed to it was largely measured on a chemically different molecule; and the one study that tested the acetylated form head-to-head with its metabolites suggested the activity, where it exists, may not belong to the parent [3].